Decipher基因组分类器与真实世界背景下前列腺癌结局的关联
这项回顾性队列研究通过转录组数据与真实世界临床数据的纵向链接,纳入58935例接受Decipher检测的前列腺癌患者。在活检标本和根治性前列腺切除标本检测者中,Decipher基因组分类器均与转移风险独立相关,且在术后患者中与生化复发风险相关。研究支持Decipher基因组分类器在当代实践中的外部预后效度。
要点
- 活检标本检测者中,Decipher评分每增加0.1单位,转移风险HR为1.21(95%CI 1.16-1.27,p<0.001)。
- 根治性前列腺切除标本检测者中,Decipher评分每增加0.1单位,转移风险HR为1.20(95%CI 1.17-1.24,p<0.001)。
- 术后检测者中,Decipher评分每增加0.1单位,生化复发风险HR为1.12(95%CI 1.10-1.14,p<0.001)。
核心结论
- 这项全国范围的真实世界转录组链接研究支持Decipher基因组分类器在当代实践管理患者中的外部预后效度。
研究设计与样本
- 回顾性队列研究,利用Decipher基因组分类器转录组数据与来自保险索赔、药房记录和电子健康记录的真实世界临床数据的纵向链接。
- 共纳入58935例接受Decipher检测的参与者,其中33379例检测活检标本,25556例检测根治性前列腺切除标本。
- 采用Kaplan-Meier和Cox比例风险回归分析,调整临床和病理因素。
主要发现
- 活检检测者中位年龄67岁(IQR 62-72),根治性前列腺切除检测者中位年龄65岁(IQR 59-69)。
- 活检检测者中位基因组分类器评分0.43(IQR 0.27-0.66),根治性前列腺切除检测者中位评分0.54(IQR 0.32-0.79)。
- 调整基线临床和病理风险因素后,基因组分类器与活检检测者转移风险独立相关(HR 1.21/0.1单位,95%CI 1.16-1.27,p<0.001)。
- 调整基线临床和病理风险因素后,基因组分类器与根治性前列腺切除检测者转移风险独立相关(HR 1.20/0.1单位,95%CI 1.17-1.24,p<0.001)。
- 调整年龄和术后前列腺癌风险评估评分后,基因组分类器与根治性前列腺切除检测者生化复发风险相关(HR 1.12/0.1单位,95%CI 1.10-1.14,p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Although the prognostic significance of the Decipher prostate cancer genomic classifier (GC) has been established largely from analyses of archival tissue, less is known about the associations between the results of Decipher testing and oncologic outcomes among patients receiving contemporaneous testing and treatment in the real-world practice setting. Our objective was to assess the associations between the Decipher GC and risks of metastasis and biochemical recurrence (BCR) following prostate biopsy and radical prostatectomy (RP) among patients tested and treated in the real-world setting. METHODS: A retrospective cohort study was conducted using a novel longitudinal linkage of transcriptomic data from the Decipher GC and real-world clinical data (RWD) aggregated from insurance claims, pharmacy records, and electronic health record data across payors and sites of care. Kaplan-Meier and Cox proportional hazards regressions were used to examine the associations between the GC and study outcomes, adjusting for clinical and pathologic factors. KEY FINDINGS AND LIMITATIONS: Metastasis from prostate cancer and BCR after radical prostatectomy, Decipher GC continuous score, and risk categories were evaluated. We identified 58 935 participants who underwent Decipher testing, including 33 379 on a biopsy specimen and 25 556 on an RP specimen. The median age was 67 yr (interquartile range [IQR] 62-72) at biopsy testing and 65 yr (IQR 59-69) at RP. The median GC score was 0.43 (IQR 0.27-0.66) among biopsy-tested patients and 0.54 (0.32-0.79) among RP-tested patients. The GC was independently associated with the risk of metastasis among biopsy-tested (hazard ratio [HR] per 0.1 unit increase in GC 1.21 [95% confidence interval {CI} 1.16-1.27], p < 0.001) and RP-tested (HR 1.20 [95% CI 1.17-1.24], p < 0.001) patients after adjusting for baseline clinical and pathologic risk factors. In addition, the GC was associated with the risk of BCR among RP-tested patients (HR 1.12 [95% CI 1.10-1.14], p < 0.001) in models adjusted for age and Cancer of the Prostate Risk Assessment postsurgical score. CONCLUSIONS AND CLINICAL IMPLICATIONS: This real-world study of a novel transcriptomic linkage conducted at a national scale supports the external prognostic validity of the Decipher GC among patients managed in contemporary practice. PATIENT SUMMARY: This study looked at the use of the Decipher genomic classifier, a test used to help understand the aggressiveness of a patient's prostate cancer. Looking at the results of 58 935 participants who underwent testing, we found that the Decipher test helped estimate the risk of cancer recurrence and metastasis.
引用
- Leapman MS, Ho J, Liu Y, et al. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. Eur Urol Oncol. 2024. PMID: 39098389. doi:10.1016/j.euo.2024.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。